Open Access

Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas

  • Authors:
    • Jing Yuan
    • Xinshuang Yu
    • Aihua Wang
    • Yan Li
    • Fengjun Liu
    • Yao Wang
    • Shanmei Sun
    • Xiuyang Bing
    • Yiming Liu
    • Juan Du
  • View Affiliations

  • Published online on: February 16, 2018     https://doi.org/10.3892/ol.2018.8082
  • Pages: 5655-5661
  • Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

For several years, the cause of autosomal recessive mental retardation has been attributed to the deletion or mutation of a gene named tumor suppressor candidate 3 (TUSC3). Previous research has identified that TUSC3 is a potential tumor suppressor gene in oral epidermoid carcinoma, lung cancer and esophageal cancer. However, to the best of our knowledge, no previously published data has existed on the expression of TUSC3 in gliomas. The present study focused on the expression of TUSC3 in brain gliomas. Additionally, the present study sought to identify he association between TUSC3 expression and the typical clinical and pathological disease manifestations of gliomas. TUSC3 levels were evaluated using a western blot assay and immunohistochemistry on tissue microarray slides. Results indicated a significant decrease in TUSC3 expression in glioma tissues compared with the normal adjacent tissues. Furthermore, TUSC3 expression and World Health Organization grade demonstrated an inverse association in patients with glioma. This revealed that lower levels of TUSC3 in gliomas may be associated with a poorly‑differentiated (high grade) tumor and thus a higher malignancy. Through the combination of the results of the present study and future research projects, TUSC3 may be a novel grading tool that assists with evaluating tumor malignancy and consequently a more active therapeutic regimen may be used in patients with glioma.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yuan J, Yu X, Wang A, Li Y, Liu F, Wang Y, Sun S, Bing X, Liu Y, Du J, Du J, et al: Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas. Oncol Lett 15: 5655-5661, 2018.
APA
Yuan, J., Yu, X., Wang, A., Li, Y., Liu, F., Wang, Y. ... Du, J. (2018). Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas. Oncology Letters, 15, 5655-5661. https://doi.org/10.3892/ol.2018.8082
MLA
Yuan, J., Yu, X., Wang, A., Li, Y., Liu, F., Wang, Y., Sun, S., Bing, X., Liu, Y., Du, J."Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas". Oncology Letters 15.4 (2018): 5655-5661.
Chicago
Yuan, J., Yu, X., Wang, A., Li, Y., Liu, F., Wang, Y., Sun, S., Bing, X., Liu, Y., Du, J."Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas". Oncology Letters 15, no. 4 (2018): 5655-5661. https://doi.org/10.3892/ol.2018.8082